KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · IEX Real-Time Price · USD
14.55
+0.35 (2.46%)
Jul 19, 2024, 4:00 PM EDT - Market closed
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for KALV stock have an average target of 24, with a low estimate of 20 and a high estimate of 32. The average target predicts an increase of 64.95% from the current stock price of 14.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KALV stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +37.46% | Jul 15, 2024 |
| Needham | Needham | Strong Buy Maintains $35 → $32 | Strong Buy | Maintains | $35 → $32 | +119.93% | Jul 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +140.55% | Jun 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $20 | Strong Buy | Maintains | $24 → $20 | +37.46% | May 3, 2024 |
| Needham | Needham | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +140.55% | May 1, 2024 |
Financial Forecast
Revenue This Year
16.41M
Revenue Next Year
120.69M
from 16.41M
Increased by 635.56%
EPS This Year
-2.61
from -3.44
EPS Next Year
-0.51
from -2.61
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 37.3M | 225.7M | 237.8M | 308.4M | 390.6M |
| Avg | 16.4M | 120.7M | 169.0M | 256.5M | 344.7M |
| Low | 5.6M | 50.7M | 129.2M | 208.8M | 272.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,275.8% | 97.1% | 82.5% | 52.3% |
| Avg | - | 635.6% | 40.0% | 51.8% | 34.4% |
| Low | - | 208.8% | 7.1% | 23.5% | 6.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.80 | 1.09 | 1.25 | 2.22 | 4.16 |
| Avg | -2.61 | -0.51 | 0.18 | 1.55 | 2.91 |
| Low | -3.24 | -1.64 | -0.53 | 0.64 | 1.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | 1,106.7% | 167.6% |
| Avg | - | - | - | 746.3% | 87.5% |
| Low | - | - | - | 246.9% | -1.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.